EPCAM: A Strategy to Enable Manufacturing-Process Control Transformation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EPCAM: A Strategy to Enable Manufacturing-Process Control Transformation
Enterprise process control and management (EPCAM) is a new strategy for healthcare manufacturers based on recent process-control breakthroughs in the electronics industry.


Pharmaceutical Technology


The five levels of control

Level 5 is the level of electronic batch records. At this level, the management of manufacturing control is improved by typically linking it to ERP and LIMS electronically. This link guards against mistakes in manual transcription. Conformance to standard operating procedures (SOPs) is increased. Better conformance reduces paperwork errors, which, in turn, ensures that correct manufacturing sequences are followed and reduces manufacturing mistakes. Paperwork is also reduced at this level, and nonconformances resulting from paperwork are significantly reduced. Process capability, however, typically does not improve, and process sigma improves only slightly. This level is a good stage at which to introduce technology to the shop floor, gain experience within operations, and reconcile and improve data.

MES characterizes Level 4. This level provides automated machine instructions that establish the process parameters in which the equipment operates. MES typically links ERP directly to the shop floor. This link reduces operator and transcription errors. Processes are standardized, and operating conditions are measured and recorded. SCADA regulatory requirements are satisfied. Messages automatically alert operators to out-of-specification operating conditions. Quality and compliance are increased by additional standardization and mistake-proofing. At this level, process capability may increase slightly if the process parameters correlated to product attributes are known. Even if this is not the immediate result, the standardization of MES provides the controlled environment that enables future process improvement.

Level 3 is marked by point-to-point process control. This level of automated process control allows users to modify product attributes by adjusting process parameters. For example, the amount of active/in.2 in a layer (patch) to be applied to a substrate may be controlled by adjusting the line speed of the coating operation. The thickness of the layer is measured after coating, and the line speed may be increased or decreased to achieve the targeted thickness. This control is an example of PAT that FDA has been encouraging during the past several years. At this level, process capability is increased for the selected operation raising it to more than 1.0 sigma. This measurement means that, most of the time, the product will be made within specification but will vary within the specifications. Quality and compliance increase, thus providing significant business results such as improved yields, reduced waste, increased capacity, and fewer errors.

Level 2 is APC. APC is the application of process control to the entire manufacturing process. The manufacturing process can be within one plant or shared among multiple plants. The process can include suppliers and contract manufacturers. APC allows operators to adjust a process based upon known data from previous operations, the condition of raw materials to be used in the process, or the known condition of the equipment tool. As in Level 3, where the thickness of the active coating on a patch is controlled by line speed, APC achieves the exact concentration of active using data about the concentration of the active in the coating batch. APC thus attains the correct thickness level based on batch concentration. APC automatically adjusts from batch to batch.

In addition, the uniformity of thickness across the patch surface is important, and the uniformity of the coating is based on the batch's viscosity, surface tension, and temperature. APC automatically adjusts machine parameters such as coating-bar vacuum, web tension, and width between coating rollers to obtain the precise uniform coating based on the batch characteristics.

A key requirement of Level 4 is the integration of data for APC. This integration should be planned ahead of time through network design. The data elements that are related through various algorithms include metrology data (which are related to products attributes such as thickness, active concentration, and color), machine parameters (e.g., current, vacuum, and motor temperature), process parameters generated by machine parameters (e.g., solution temperature, pressure, line speed, machining speeds, and feeds), logistics data (which identify the material batch and location), event data (such as material consumed and steps completed within an equipment unit), and other local data from the tool bus such as sensor data.

APC uses various algorithms to determine the relationship between the product attributes and the machine and process variables. Based on these relationships, APC controls multiple process steps to achieve the desired product attributes. APC operates in feed-forward and feedback modes as required. Analysis is performed from unit-operations and multivariate perspectives. Because of its multivariate capability, applying APC improves the process performance to more than 2.0 CpK.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here